rs34557412 — TNFRSF13B TACI C104R

Missense variant in the TACI receptor's cysteine-rich ligand-binding domain that dominantly disrupts BAFF/APRIL signaling; the strongest non-HLA association with infection susceptibility and a known cause of common variable immunodeficiency and IgA deficiency

See your personal result for TNFRSF13B

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TACI C104R — When the B-Cell's Survival Signal Goes Silent

Every antibody that defends you against a repeated infection — from the IgA that coats your gut to the IgG that neutralises a pathogen in your blood — depends on a molecular conversation between B cells and their survival signals. TACI (Transmembrane Activator and Calcium modulator and cyclophilin ligand Interactor)11 TACI (Transmembrane Activator and Calcium modulator and cyclophilin ligand Interactor)
TACI is encoded by TNFRSF13B and expressed mainly on mature B cells and plasma cells; it binds the cytokines BAFF and APRIL to regulate B-cell differentiation, class-switch recombination, and immunoglobulin secretion is the receptor that receives those survival signals. The C104R variant (rs34557412) swaps a cysteine for an arginine at position 104 in TACI's ligand-binding domain — precisely the cysteine residue that forms a disulfide bridge required for proper receptor folding. The result is a malformed receptor that cannot bind its ligands and, more dangerously, actively sabotages the wild-type copies it assembles with.

This makes C104R the most consequential known non-HLA risk factor for infection susceptibility and the most penetrant genetic cause of common variable immunodeficiency (CVID). It is rare — about 1% of Europeans carry one copy — but the functional consequences in carriers are measurable at the population level and clinically serious in a subset.

The Mechanism

TACI forms oligomeric receptor complexes before ligand binding — the subunits pre-assemble in the membrane even before BAFF or APRIL arrives. This is critical for understanding why C104R is so damaging. Because the mutant receptor integrates into the same oligomeric complex as wild-type TACI, it cannot be simply ignored. Garibyan et al. demonstrated in 200722 Garibyan et al. demonstrated in 2007
the dominant-negative effect was confirmed by co-immunoprecipitation in cells co-expressing WT and C104R TACI; the corresponding murine mutant C76R showed identical effects that C104R dominantly interferes with signaling by blocking ligand-induced receptor rearrangement — not by preventing ligand binding itself, but by freezing the oligomeric complex in a non-signaling conformation. A single mutant subunit can silence the entire receptor cluster.

The downstream consequences are predictable: without TACI signaling, B cells fail to undergo class-switch recombination33 class-switch recombination
the process by which B cells change from producing IgM to producing IgG, IgA, or IgE — essential for producing antibodies tailored to the pathogen's surface. Without class switching, the adaptive immune response cannot generate the specific, high-affinity antibodies that prevent re-infection. B cells from C104R carriers express surface TACI normally but produce negligible IgG and IgA in response to APRIL stimulation. At the chromatin level, multi-omics analysis44 multi-omics analysis
naïve B cells from C104R carriers showed 8% less accessible chromatin at baseline; class-switched memory B cells showed 25% less reveals a genome-wide silencing of B-cell activation programs — with dysregulated NF-κB and MAPK signalling confirmed by flow cytometry.

The Evidence

Discovery and CVID connection. Two concurrent Nature Genetics papers in 200555 Nature Genetics papers in 2005
Castigli et al. and Salzer et al. were published back-to-back and together established TNFRSF13B as the first non-HLA gene associated with CVID established TNFRSF13B mutations as a cause of CVID and IgA deficiency. Castigli et al. found TACI mutations in 4 of 19 CVID patients and 1 of 16 IgAD patients, absent in all 50 healthy controls. Salzer et al. identified mutations in 13 CVID patients, with homozygous C104R abolishing APRIL binding and class switching entirely. Combined population analysis found TNFRSF13B mutation frequency of 9.9% in CVID patients vs. 3.2% in controls66 TNFRSF13B mutation frequency of 9.9% in CVID patients vs. 3.2% in controls
p<10⁻⁶ across Czech, Canadian, and European populations; C104R was the most frequent single mutation detected.

Infection susceptibility at the population level. A [genome-wide association study of

200,000 Europeans | Tian et al. Nature Communications 2017; 23 infection phenotypes tested including tonsillectomy, childhood ear infection, strep throat, pneumonia, and others](https://pubmed.ncbi.nlm.nih.gov/28928442/77 https://pubmed.ncbi.nlm.nih.gov/28928442/) found rs34557412 to be the strongest non-HLA association with infection susceptibility, with an odds ratio of 1.59 (p=3×10⁻²¹) for tonsillectomy and nominally significant association with childhood ear infection (p=2×10⁻⁶). Tonsillectomy in this context is a proxy for recurrent tonsillitis — the tonsillar B-cell microenvironment is particularly dependent on TACI-mediated switching to IgA, and its failure manifests as chronic mucosal infections requiring surgical removal.

Blood cell effects. A large GWAS of haematological traits88 large GWAS of haematological traits
Astle et al. Cell 2016; 127,000+ individuals from UK Biobank and other cohorts found significant associations between the G allele and reduced monocyte count (p=3×10⁻²⁷), reduced lymphocyte count (p=2×10⁻¹⁰), and reduced platelet count (p=2×10⁻¹¹). These effects reflect TACI's role in shaping the composition of circulating immune cells, consistent with impaired B-cell differentiation and survival.

Autoimmunity paradox. Despite causing immunodeficiency, C104R carriers paradoxically show elevated autoimmune complications. This reflects a fundamental feature of TACI biology: TACI is not only a survival signal but also a negative regulator of autoreactive B cells. Heterozygous carriers show impaired elimination of autoreactive clones — the dominant-negative mechanism disrupts both the pro-survival and the tolerance-maintaining arms of TACI signalling.

Practical Actions

The actionable implications of C104R focus on immunoglobulin monitoring and infection vigilance. Carriers who develop symptomatic hypogammaglobulinemia (low IgG or IgA) may qualify for immunoglobulin replacement therapy, which is highly effective at preventing recurrent bacterial infections in CVID. Even asymptomatic carriers warrant baseline immunoglobulin quantification, as subclinical IgA or IgG deficiency may go unrecognized until a serious infection occurs.

For heterozygous carriers, the dominant-negative mechanism means the practical risk lies between the normal and homozygous extremes. Many heterozygous C104R carriers remain subclinically affected — their infection burden is elevated but they do not meet formal CVID diagnostic criteria. Regular immunoglobulin monitoring and a low threshold for medical evaluation of recurrent infections are the cornerstones of management.

Interactions

CVID is polygenic in most cases. TACI mutations are neither necessary nor sufficient for CVID — they increase susceptibility, and additional genetic or environmental triggers determine whether frank immunodeficiency develops. Combinations with variants in BAFF (rs9514828, rs1048990), the BAFF receptor TNFRSF13C, or MSH5 at the MHC region have been proposed as modifiers. The GWAS data showing tonsillectomy association (OR 1.59) reflects the penetrance of the variant in an unselected general population — most G allele carriers do not have a formal CVID diagnosis but carry measurable immune disadvantage across their lifetime.

Genotype Interpretations

What each possible genotype means for this variant.

AA Non-Carrier Normal

Standard TACI function with normal B-cell class switching and immunoglobulin production

You carry two copies of the common reference allele at rs34557412, meaning your TACI receptor has the normal cysteine-104 residue with intact ligand-binding domain structure. Your B cells can fully respond to BAFF and APRIL signals, completing class-switch recombination to produce IgA, IgG, and IgE at normal levels. About 99% of people share this genotype. You do not carry the dominant-negative TACI variant associated with increased infection susceptibility, common variable immunodeficiency, or IgA deficiency.

AG Carrier Carrier

One copy of the dominant-negative TACI C104R variant — elevated infection susceptibility and CVID/IgA deficiency risk

The dominant-negative mechanism sets this variant apart from typical heterozygous carriers. Because TACI pre-assembles as an oligomeric receptor complex before any ligand arrives, the C104R subunit integrates into the complex and freezes it in a non-signaling state — even when wild-type subunits are present. Garibyan et al. (2007, JCI) demonstrated this mechanism directly: C104R and its murine equivalent C76R both exert their dominant effect through preassociation with wild-type TACI, not through ligand competition.

The population-level consequence is captured in two independent large GWAS. The 23andMe-based infection GWAS (Tian et al. 2017, OR 1.59 for tonsillectomy, n>200,000) represents unselected general population data, while combined clinical cohort analysis shows TNFRSF13B mutations in 9.9% of CVID patients vs. 3.2% of healthy controls. Together, these data indicate that C104R shifts the entire distribution of immune competence in carriers — increasing both symptomatic disease risk and subclinical vulnerability.

Many AG carriers will also show measurable reductions in circulating monocyte count, lymphocyte count, and platelet count (Astle et al. 2016) — a systemic immune phenotype detectable on routine blood counts that may be an early indicator of the variant's effect.

GG Homozygous Carrier Homozygous

Homozygous TACI C104R — high penetrance for CVID or severe antibody deficiency with substantially elevated infection risk

Homozygous C104R was among the first mutations characterised in the Salzer et al. 2005 Nature Genetics study establishing TNFRSF13B as a CVID gene. A patient homozygous for C104R showed abolished APRIL binding and profoundly deficient class switching in B-cell functional assays — a result consistent with complete TACI loss-of-function, not merely haploinsufficiency.

The dominant-negative mechanism adds an additional layer: even with homozygous C104R, the mutant subunits still pre-assemble into oligomeric TACI complexes. In the homozygous state, every receptor complex in every B cell is assembled exclusively from ligand-binding- defective subunits, ensuring complete signaling failure.

Most individuals with this genotype will either already carry a CVID diagnosis or will present with recurrent, severe, or unusual infections during childhood or early adulthood. Serum immunoglobulin levels will typically show pan-hypogammaglobulinemia (low IgG, IgA, and IgM). Immunoglobulin replacement therapy — intravenous (IVIG) or subcutaneous (SCIG) — is the standard of care for CVID and is highly effective at reducing infection frequency and severity when administered appropriately.